Functional differences between full and partial agonists: Evidence for ligand-specific receptor conformations

Journal of Pharmacology and Experimental Therapeutics

Volumn 297, Issue 3, 2001, Pages 1218-1226

  Seifert, Roland ^a,c   Wenzel Seifert, Katharina ^a,c   Gether, Ulrik ^b,c   Kobilka, Brian K ^c,d  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATASE; HYBRID PROTEIN;

ANIMAL CELL; ARTICLE; COMPLEX FORMATION; CONFORMATION; CONTROLLED STUDY; DISSOCIATION; DRUG RECEPTOR BINDING; HYDROLYSIS; MOLECULAR STABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; CELL LINE; CELL MEMBRANE; GENE EXPRESSION; GTP PHOSPHOHYDROLASES; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; HETEROTRIMERIC GTP-BINDING PROTEINS; LIGANDS; MACROMOLECULAR SUBSTANCES; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SPODOPTERA;

EID: 0034996884     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. s-adenylate cyclase interactions. FASEB J 5:2300-2303.
2. 2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 269:11687-11690.
3. Blake AD, Bot G, Freeman JC and Reisine T (1997) Differential opioid agonist regulation of the mouse μ opioid receptor. J Biol Chem 272:782-790.
4. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, et al. (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339.
5. 3H-naloxone benzoylhydrazone binding in MOR-1-transfected Chinese hamster ovary cells: evidence for G-protein-dependent antagonist binding. J Pharmacol Exp Ther 268:376-381.
6. 1B-adrenergic receptor signal-inactivating point mutation. EMBO J 19:4265-4271.
7. Chidiac P, Hebert TE, Valiquette M, Dennis M and Bouvier M (1994) Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 45:490-499.
8. Chiu TT, Yung LY and Wong YH (1996) Inverse agonistic effect of ICI-174,864 on the cloned δ-opioid receptor: role of G protein and adenylyl cyclase activation. Mol Pharmacol 50:1651-1657.
9. Colquhoun D (1998) Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutated receptors. Br J Pharmacol 125:924-947.
10. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at δ opioid receptors. Proc Natl Acad Sci USA 86:7321-7325.
11. Gether U and Kobilka BK (1998) G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem 273:17979-17982.
12. 2 adrenergic receptor. Evidence for ligand-specific conformational changes. J Biol Chem 270: 28268-28275.
13. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H and Kobilka BK (1997) Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 272:2587-2590.
14. Gilman AG (1987) G proteins: transducers of receptor-generated signals. Annu Rev Biochem 56:615-649.
15. s. J Biol Chem 265:1388-1393.
16. Hoyer D and Boddeke HW (1993) Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 14:270-275.
17. 3 subtype is essential for activation of GTP-binding protein. Eur J Biochem 224:161-166.
18. Jinnah HA, Page T and Friedmann T (1993) Brain purines in a genetic mouse model of Lesch-Nyhan disease. J Neurochem 60:2036-2045.
19. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans CJ and von Zastrow M (1996) Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271:19021-19024.
20. Kenakin T (1996a) The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 48:413-463.
21. Kenakin T (1996b) Receptor conformational induction versus selection: all part of the same energy landscape. Trends Pharmacol Sci 17:190-191.
22. Kenakin T (1997) Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci 18:456-464.
23. Kent RS, De Lean A and Lefkowitz RJ (1980) A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. Mol Pharmacol 17:14-23.
24. Klinker JF, Laugwitz K-L, Hagelüken A and Seifert A (1996) Activation of GTP formation and high-affinity GTP hydrolysis by mastoparan in various cell membranes. G-protein activation via nucleoside diphosphate kinase, a possible mechanism of mastoparan action. Biochem Pharmacol 51:217-223.
25. Kobilka BK (1992) Adrenergic receptors as models for G protein-coupled receptors. Annu Rev Neurosci 15:87-114.
26. s complex: evidence for agonist-specific states. Mol Pharmacol 52:144-154.
27. Leeb-Lundberg LM, Mathis SA and Herzig MC (1994) Antagonists of bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells. J Biol Chem 269:25970-25973.
28. Lefkowitz RJ, Cotecchia S, Samama P and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307.
29. Milligan G (2000) Insights into ligand pharmacology using receptor-G-protein fusion proteins. Trends Pharmacol Sci 21:24-28.
30. Otero AS (1990) Transphosphorylation and G protein activation. Biochem Pharmacol 39:1399-1404.
31. s. J Biol Chem 263:9482-9485.
32. 2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther 280:576-583.
33. 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
34. 2-adrenergic receptor. Mol Pharmacol 45:390-394.
35. sα fusion protein. Eur J Biochem 255:369-382.
36. sα has properties of a constitutively active receptor. J Biol Chem 273:5109-5116.
37. s interactions: evidence for multiple receptor conformations. Mol Pharmacol 56:348-358.
38. α fusion proteins: an approach for the molecular analysis of receptor/G-protein coupling. Trends Pharmacol Sci 20:383-389.
39. 2 receptor contains positive and negative signals important for signal transduction and receptor down-regulation. J Neurochem 67:1791-1800.
40. 1A) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state. J Biol Chem 275:2893-2900.
41. Tucek S (1997) Is the R and R* dichotomy real? Observations of allosteric phenomena on G protein-coupled receptors point to problems in the interpretation of agonist-receptor-G protein interactions. Trends Pharmacol Sci 18:414-416.
42. i guanine-nucleotide-binding regulatory protein regulate receptor internalization. Eur J Biochem 222:525-531.
43. 3. J Biol Chem 274:33259-33266.
44. q-proteins. Mol Pharmacol 58:954-966.
45. Wieland T and Jakobs KH (1992) Evidence for nucleoside diphosphokinase-dependent channeling of guanosine 5′-(γ-thio)triphosphate to guanine nucleotide-binding proteins. Mol Pharmacol 42:731-735.
46. Wess J (1997) G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J 11:346-354.
47. 2+ current in mouse ventricular myocytes. Mol Pharmacol 56:485-493.
48. 2-adrenergic receptor. J Biol Chem 273:3401-3407.